NCT06227754 OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
| NCT ID | NCT06227754 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chonnam National University Hospital |
| Condition | ST Elevation Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2024-03-25 |
| Primary Completion | 2031-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,500 participants in total. It began in 2024-03-25 with a primary completion date of 2031-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).
Eligibility Criteria
Inclusion Criteria: * Subject must be at least 19 years of age * Acute ST-segment elevation myocardial infarction (STEMI) \*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1 * Primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients * Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Exclusion Criteria: * Target lesions not amenable for PCI by operators' decision * Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion) * Creatinine clearance ≤30 ml/min/1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance) * Cardiogenic shock (Killip class IV) at presentation * Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus * Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock) * Pregnancy or breast feeding * Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment) * Unwillingness or inability to comply with the procedures described in this protocol
Contact & Investigator
Young Joon Hong, MD, PhD
PRINCIPAL INVESTIGATOR
Chonnam National University
Frequently Asked Questions
Who can join the NCT06227754 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying ST Elevation Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06227754 currently recruiting?
Yes, NCT06227754 is actively recruiting participants. Contact the research team at lsh8602@naver.com for enrollment information.
Where is the NCT06227754 trial being conducted?
This trial is being conducted at Daegu, South Korea, Daegu, South Korea, Daegu, South Korea, Gwangju, South Korea and 11 additional locations.
Who is sponsoring the NCT06227754 clinical trial?
NCT06227754 is sponsored by Chonnam National University Hospital. The principal investigator is Young Joon Hong, MD, PhD at Chonnam National University. The trial plans to enroll 1,500 participants.